Mycenax Biotech to Integrate RIN’s Next-Gen ADC Linker into Global CDMO Services

• Mycenax Biotech has signed a letter of intent with RIN Institute to incorporate proprietary ADC linker technology into its CDMO services.

• The agreement includes an exclusive licence to use RIN’s linker patents in the EU, US, China, Japan, and other regions.

Mycenax Biotech Inc. has entered into a strategic collaboration with Japan-based RIN Institute Inc. through a signed Letter of Intent (LOI), aiming to strengthen its contract manufacturing services in the antibody-drug conjugate (ADC) field.

The agreement grants Mycenax and its ADC alliance, Krisan Biotech, exclusive rights to incorporate RIN’s proprietary linker technology into their CDMO offering. This licence covers several key markets including the EU, US, China, and Japan. The linker has demonstrated improved anti-tumour efficacy and serum stability, with RIN having filed a patent for the innovation in November 2024.

This exclusive access will enable Mycenax to deliver differentiated and competitive ADC solutions to global pharmaceutical partners, enhancing both development outcomes and manufacturing efficiency.

In addition to the licensing agreement, Mycenax is currently contracted to manufacture RIN’s lead investigational anti-TMEM180 antibody, which is undergoing Phase 1 trials. It has also completed production of a high-quality ADC with a drug-to-antibody ratio (DAR) of 8 for RIN’s pipeline candidate anti-IF-ADC.